Develops oral small-molecule drugs targeting GPCRs for patients with endocrine, immune and inflammatory, and metabolic diseases.
10-K for FY2025, filed Mar 9, 2026
Revenue comes from research services and licenses under collaborations: partners fund research and development work, may pay upfront and milestone amounts, and may owe royalties on approved drug sales. The company has not generated revenue from product sales.
10-K for FY2025, filed Mar 9, 2026The Company’s revenues are primarily derived through its license and research and development service arrangements. Payments to the Company…View ↗
Research and development services - The promises under the Company's collaboration agreement include research and development services to…View ↗
Licenses of intellectual property, or IP - If the license to the Company’s IP is determined to be distinct from the other performance…View ↗
We have incurred significant operating losses since our inception, except for the year ended December 31, 2023. Our revenue to date has…View ↗
$46M
10-K for FY2025, filed Mar 9, 2026
$46M ↗
Pharmaceutical partners buy licenses and research and development services through collaboration agreements; Novo funds research work, and Vertex is also a customer.
10-K for FY2025, filed Mar 9, 2026For the year ended December 31, 2025, the Company's revenue is comprised solely of arrangements with Novo and Vertex. For the year ended…View ↗
On May 13, 2025, the Company entered into a Collaboration and License Agreement with Novo (the “Novo Collaboration Agreement”). Under the…View ↗
Upon effectiveness of the Novo Collaboration Agreement on July 1, 2025, the Company and Novo have commenced four simultaneous research and…View ↗
The Company concluded the Agreement is not within the scope of Accounting Standards Codification 808, Collaborative Arrangements as the…View ↗
Not on paper. It lost $48.9M in FY2025, but brought in more cash than it spent: $109.7M of free cash flow.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$26.6MView ↗
8-K, filed Nov 4, 2026
SEP-204 is a potent and selective oral small molecule thyroid-stimulating hormone receptor (TSHR) negative allosteric modulator (NAM).…View ↗
8-K, filed Apr 13, 2026
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of…View ↗
Loading...